NYSE:VNRX
VOLITIONRX LTD Stock News
$0.720
-0.0593 (-7.61%)
At Close: May 07, 2024
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
04:54am, Thursday, 18'th Jan 2024
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession,
VolitionRx has 'compelling plans' to advance veterinary care in 2024
09:41am, Thursday, 04'th Jan 2024
VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023. Among the notable achievements in the past year, Volition successfully launched
Volition secures €5M in financing from Belgium's Wallonie Entreprendre
09:06am, Tuesday, 05'th Dec 2023
VolitionRx (NYSE-A:VNRX) told investors it has secured €5 million (roughly $5.5 million) in financing from Belgium's Wallonie Entreprendre (WE) for the ongoing development of its Nu.Q product portfo
VolitionRx Limited (VNRX) Q3 2023 Earnings Call Transcript
03:41pm, Wednesday, 15'th Nov 2023
VolitionRx Limited (NYSE:VNRX ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - Presid
VolitionRx's Nu.Q Vet Cancer Test sees five-fold revenue surge in 2023
05:18pm, Tuesday, 14'th Nov 2023
VolitionRx (NYSE-A:VNRX) said its Nu.Q Vet Cancer Test revenue has seen a nearly five-fold increase in sales over the first nine months of 2023 compared to the same period last year. The Nu.Q test inv
VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update
08:00am, Wednesday, 08'th Nov 2023
Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx joins up with VPG to launch Nu.Q Vet Cancer Test in UK and Ireland
08:07am, Monday, 06'th Nov 2023
VolitionRx (NYSE-A:VNRX) told investors it has joined forces with Veterinary Pathology Group (VPG) to launch the Nu.Q Vet Cancer Test to veterinary practices in the UK and Ireland. The NuQ Vet Cancer
VolitionRx highlights study demonstrating Nu.Q NETs is promising biomarker for septic shock
09:32am, Thursday, 19'th Oct 2023
VolitionRx (NYSE-A:VNRX) has highlighted a recently published paper in Annals of Intensive Care which shows the company's Nu.Q NETs test is a promising biomarker for the evaluation of disease severity
VolitionRx welcomes US Ambassador to Belgium for exclusive tour of research facilities
12:35pm, Wednesday, 18'th Oct 2023
VolitionRx (NYSE-A:VNRX), the multinational epigenetics company, said it was “delighted” to host Ambassador Michael Adler, the US Ambassador to the Kingdom of Belgium, for an exclusive tour of its
VolitionRx to present cancer detection abstracts at European oncology conference
10:11am, Monday, 16'th Oct 2023
VolitionRx (NYSE-A:VNRX) said it will be presenting three scientific abstracts about cancer detection tools at the annual congress of the European Society for Medical Oncology (ESMO) 2023. "We are del
VolitionRx holds roundtable on sepsis management
08:35am, Friday, 13'th Oct 2023
VolitionRx (NYSE-A:VNRX) has revealed insights from a recent Key Opinion Leader (KOL) roundtable focused on sepsis management. The KOL roundtable brought together a panel of leading experts in sepsis
VolitionRx to unveil new cancer detection method insights at upcoming webinar
09:22am, Monday, 02'nd Oct 2023
VolitionRx (NYSE-A:VNRX) Limited has announced that it is participating in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21 at ESMO 2023, the annual congres
VolitionRx to host sepsis management roundtable
08:37am, Wednesday, 13'th Sep 2023
VolitionRx (NYSE-A:VNRX) said it is hosting a roundtable discussion in Athens this weekend which will bring together world-renowned experts in sepsis, a life-threatening condition that occurs in respo
VolitionRx Limited (VNRX) Q2 2023 Earnings Call Transcript
12:27pm, Tuesday, 15'th Aug 2023
VolitionRx Limited (NYSE:VNRX ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - Founder
VolitionRx Limited prices major public offering to fund research and product development
01:31pm, Thursday, 01'st Jun 2023
VolitionRx (NYSE-A:VNRX) Limited announced the pricing of an underwritten public offering with expected gross proceeds of $16.5 million. The epigenetics company plans to offer 13 million shares at $1.